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DISCLAIMER: This is a theoretical proposal done as an intellectual exercise.  
 
Abstract 
This is a theoretical proposal done as an intellectual exercise. The purpose of 
this project is to practice and familiarize oneself with the process of applying for a grant 
from the National Institute of Health to conduct research on human subjects. This 
proposed study plans to sequence blood samples from infected individuals, exposed 
and uninfected individuals, and unexposed individuals from the 2018 outbreak in the 
Democratic Republic of Congo to determine the presence of polymorphisms in TNF 
production as they relate to Ebolavirus infection. It is hypothesized that certain 
polymorphisms in the regulation and production of TNF that cause a decreased 
production thereof have a protective effect against Ebola disease. This hypothesis is 
based on a synthesis of other’s published work. Completion of this study will identify key 
polymorphic targets for developing interventions and allocating healthcare resources 
during a potential future Ebola epidemic in the Democratic Republic of Congo. The work 
proposed here will also develop experimental techniques and understanding of 
infectious disease immunology and genetics that together will constitute a widely-
applicable platform for assessing risk during other disease outbreaks.  
 
  
DISCLAIMER: This is a theoretical proposal done as an intellectual exercise.  
Table of Contents 
Title Page……………………….……………………….……………………….………………1 
Abstract….……………………….……………………….……………………….……………..2 
Table of Contents….……………………….……………………….……………………….….3 
Body of Thesis….……………………….……………………….……………………….……..4 
 Project Title….……………………….……………………….………………………….4 
 Project Summary/Abstract….……………………….……………………….………...4 
 Project Narrative….……………………….……………………….……………………5 
 Specific Aims….……………………….……………………….………………………..6 
 Research Strategy ….……………………….……………………….…………………8 
  Significance….……………………….……………………….…………………8 
  Innovation……………………….……………………….……………………..10 
  Approach…………….………………….………………….…………………..10 
   Research Personnel……….………………….………….…………...10 
Specific Aim 1…………….………………….………………….……..11 
   Specific Aim 2…………….………………….………………….……..13 
   Use of Human Subjects…………….………………….……………..15 
References…………….………………….………………….………………….……………..16 
  
DISCLAIMER: This is a theoretical proposal done as an intellectual exercise.  
Project Title:  
Determining polymorphisms in TNF production as they relate to infection with EBOV 
 
Project Summary/Abstract:  
Ebola virus has surfaced several times since its discovery in 1976 to cause 
devastating outbreaks in the continent of Africa. The most recent outbreak took place in 
the Democratic Republic of Congo (DRC) from 2018-2020. This was the largest Ebola 
outbreak in the DRC, and the second largest Ebola outbreak in the world. Better 
methods for diagnosis and intervention are necessary to prevent future outbreaks from 
becoming worse. This proposed study plans to sequence blood samples from infected 
individuals, exposed and uninfected individuals, and unexposed individuals from the 
2018 outbreak in the North Kivu province of the Democratic Republic of Congo to 
determine the presence of polymorphisms in TNF production as they relate to 
Ebolavirus infection. It is hypothesized that certain polymorphisms in the regulation and 
production of TNF that cause a decreased production thereof have a protective effect 
against severe Ebola disease. This hypothesis is based on a synthesis of other’s 
published work. Completion of this study will identify key polymorphic targets for 
developing interventions and allocating healthcare resources during a potential future 
Ebola epidemic in the Democratic Republic of Congo or elsewhere. The work proposed 
here will also develop experimental techniques and understanding of infectious disease 
immunology and genetics that together will constitute a widely-applicable platform for 
assessing risk during other disease outbreaks.  
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Project Narrative:  
The proposed research is relevant to public health because it will allow 
physicians and healthcare workers to determine whether a patient is more or less at risk 
of succumbing to Ebola before infection even occurs. This could determine when and 
where interventions to stop disease course and spread should occur. This proposal is 
relevant to the part of NIH’s mission that pertains to fostering fundamental creative 
discoveries and innovative research strategies as a basis for ultimately protecting 
health. 
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Specific Aims:  
This proposal’s objective is to determine the impact that polymorphisms in TNF 
production have on Ebola disease progression.  
Infection with Ebolavirus is characterized by an abnormal host immune response 
known as a cytokine storm. A cytokine storm is when vast quantities of different 
inflammatory cytokines are produced in a short period of time. One of these cytokines 
is the tumor necrosis factor, or TNF. This cytokine is responsible for signaling cells to 
apoptosis. Therefore, a sudden influx of TNF would result in mass cell death, leading to 
organ failure and death in Ebola patients. A polymorphism preventing increased TNF 
production would theoretically aid in preventing increased cell death and organ 
damage in an individual. The work we propose to conduct will determine whether this 
is true, as well as open new possibilities for study in TNF polymorphisms and their 
relation to Ebolavirus.  
Our long-term goal is to explore genetic risk factors as they relate to Ebola 
disease by examining blood samples. Here, our central hypothesis is that certain 
polymorphisms in the regulation and production of TNF that cause a decreased 
production have a protective effect against Ebola disease. This hypothesis is based on 
a synthesis of other’s published work. The rationale is that completion will identify key 
polymorphic targets for developing interventions and allocating healthcare resources 
during a potential future Ebola epidemic in the Democratic Republic of Congo. The work 
we propose here will also develop experimental techniques and understanding of 
infectious disease immunology and genetics that together will constitute a widely-
applicable platform for assessing risk during other disease outbreaks.  
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We will test our central hypothesis and attain our objective via the following 
specific aims: 
1: To determine whether there is a polymorphism in TNF production. For this, we 
will use blood samples from uninfected and unexposed individuals and infect them with 
either activated or inactivated Ebola virus. We will also use ELISA assays to examine 
the levels of TNF produced upon infection. A DNA sequencer will be used to determine 
whether samples that produced less TNF contained a polymorphism that led to this 
diminished production. Working hypothesis: Individuals who have lower TNF production 
upon infection with Ebola have a polymorphism in the TNF-alpha gene.  
2: To determine the role of TNF in Ebola disease progression. For this, we will use 
blood serums of recently infected individuals, as well as serums throughout their 
disease progression. ELISA assays will be used to examine the levels of TNF, and 
when they are varying. We will simultaneously measure the levels of cytokines related 
to TNF. This aim is not completely dependent on the first aim, as there may or may not 
be a genetic difference between samples. Working hypothesis: Mortality will be 
dependent on high levels of TNF, with low levels being protective against death from 
Ebola. 
The expected outcome of this work is a comprehensive understanding of how 
genetic capabilities of TNF production may be a risk factor for succumbing to Ebola 
disease. The results will have an important positive impact because they lay the 
groundwork to develop further studies on understanding the role of TNF in Ebola. 
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Research Strategy: 
A) Significance: 
Ebola virus was discovered in the 1970s in what is now the Democratic Republic of 
Congo (Feldmann et al 2011). The virus causes a hemorrhagic fever that currently has 
a 60% mortality rate (Feldmann et al 2011). Transmission between humans occurs 
through contact with bodily fluids including saliva and blood.  
Research into how exactly the virus works in the body is limited, since outbreaks 
usually occur in remote areas where data collection is difficult. However, it is known that 
Ebola infection is characterized by a cytokine storm immune response in the host 
(Feldmann et al 2011). A cytokine storm is when different inflammatory cytokines are 
produced at a significantly higher rate than what is considered normal.  
Infection with Ebolavirus triggers the expression of several inflammatory cytokines 
including interferons, interleukins 2, 6, 8, and 10, interferon-inducible protein 10, 
monocyte chemoattractant protein 1, TNFα, and reactive oxygen and nitrogen species 
(Wauquier et al, 2010). Although monocytes or macrophages seem to produce many of 
these cytokines, as shown in vitro, other cell types could produce inflammatory 
cytokines in the intact animal or person. Overall, virus-induced expression of these 
cytokines seems to result in an immunological imbalance that partly contributes to the 
progression of disease. Proinflammatory responses recorded in fatal cases of Ebola 
hemorrhagic fever are dysregulated, whereas early and well-regulated inflammatory 
responses have been associated with recovery (Wauquier et al, 2010).  
Inhibition of the type I interferon response is a key feature of filovirus pathogenesis. 
The Ebola virus viral protein (VP) 35 functions as a type I interferon antagonist, by 
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blocking activation of interferon regulatory factor 3 and possibly by preventing 
transcription of interferon β (Wauquier et al, 2010). Additionally, other studies suggest 
that expression of VP24 of the Ebola virus interferes with type I interferon 
signaling; mutations in VP24 have been linked to adaptation of Zaire Ebola virus to 
produce lethal disease in mice and Guinea pigs (Feldmann et al, 1999). 
Results from several studies show an important role for reactive oxygen and 
nitrogen species in pathogenesis of Ebola hemorrhagic fever (Hensley et al, 2002). 
Increased concentrations of nitric oxide in blood were reported in non-human primates 
experimentally infected with Zaire Ebola virus and were noted in patients infected with 
Zaire Ebola virus and Sudan Ebola virus. Increased blood concentrations of nitric oxide 
in patients were associated with mortality. Abnormal production of nitric oxide has been 
associated with several pathological disorders including apoptosis of bystander 
lymphocytes, tissue damage, and loss of vascular integrity, which might contribute to 
virus-induced shock. Nitric oxide is an important mediator of hypotension, and 
hypotension is a prominent finding in most of the viral hemorrhagic fevers including 
those caused by Ebola virus (Hensley et al, 2002). 
Lymphocytes are depleted by apoptosis even though they are not susceptible to 
Ebola infection, and the apoptosis is likely to be due to impairment of dendritic cells, 
proapoptotic factors from activated monocytes/macrophages and direct effect of viral 
glycoproteins (Morikawa et al, 2007). 
In summation, an impaired and ineffective host innate immune response leads to 
high concentrations of virus and proinflammatory mediators in the late stages of 
disease, which is important in the pathogenesis of hemorrhage and shock. The 
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prevailing data suggest that infection and activation of antigen-presenting cells is 
fundamental to the development of Ebola hemorrhagic fever. The release of 
proinflammatory cytokines, chemokines, and other mediators from antigen presenting 
cells, and perhaps other cells, causes impairment of the vascular and coagulation 
systems leading to multiorgan failure and a syndrome that in some ways resembles 
septic shock. The goal of this proposed study is to determine whether the genetic 
variation in cytokines released during the cytokine storm (TNF specifically) determines 
the outcome of disease.  
B) Innovation: 
The common approaches to studying disease progression of Ebolavirus is to infect 
primates, mice, or other model organisms and observe the outcome. This study will 
build upon what is already known by using human blood samples in two different and 
novel ways. First, unexposed samples will be infected with Ebolavirus to determine the 
difference in TNF production. Second, samples of infected individuals will be used to 
observe TNF and cytokine production in relation to disease progression. Our approach 
will allow for clear results that will either support or deny our hypotheses.  
C) Approach: 
Research Personnel:  
This will be a joint effort between the Ebola Treatment Center at the Beni 
General Hospital in Beni, DRC, and the National Institute of Allergy and Infectious 
Disease Integrated Research Facility in Frederick, Maryland and both their staff.  
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Specific Aim 1: To determine whether there is a polymorphism in TNF production. 
Introduction:  
The objective of this aim is to determine what polymorphisms occur in the TNF-
alpha gene and how those affect TNF production upon infection with Ebolavirus. At this 
point, there is no specific polymorphisms in mind, any and all will be sequenced and 
vetted equally against the regular TNF-alpha gene. The working hypothesis of this aim 
is that a polymorphism in the TNF-alpha gene is seen in samples that produce lower 
levels of TNF. Our approach to testing this working hypothesis will be to use ELISA 
assays to measure TNF levels and to use DNA sequencers to sequence the TNF-alpha 
genes.   
Justification and Feasibility:  
Several TNF-alpha polymorphisms associated with TNF production have been 
identified. There have studies where lowered TNF production due to a polymorphism 
have been beneficial, such as with tuberculosis where reduced production of TNF due 
to polymorphisms leads to the inability of the tuberculosis to maintain its granuloma, 
garnering protection (Correa et al, 2005). Other studies have observed that lowered 
TNF promotes infection, such as with chronic hepatitis B, where low TNF production is 
linked to defective viral clearance (Zum et al, 1998). Most studies, however, describe 
TNF’s relationship with autoimmune disease rather than infectious diseases. Since 
there is a lot unknown about TNF polymorphisms reacting to foreign infections, this 
proposed study will only add to the limited resources in the field.  
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Research Design:  
This aim will be completed in three parts. The first part will be accomplished by 
obtaining, storing, and infecting blood samples from individuals who were uninfected 
and unexposed to Ebolavirus in the areas surrounding Beni. These surrounding areas 
will be from the Tshopo and Maniema provinces, as they were less affected by the 
outbreak, and are more likely to have unexposed individuals (Mbala-Kingebeni et al, 
2021). The second part will be accomplished by using commercially available ELISA 
kits according to manufacturer’s directions to measure the levels of TNF produced upon 
infection. The assays will be performed 5 days post infection, as this is considered late 
stage disease and will have been sufficient time to allow for TNF production (Hensley et 
al, 2002). The third part will be accomplished by using a DNA sequencer to determine 
whether samples that produced less TNF contained a polymorphism that led to this 
diminished production. All polymorphisms found will be considered and ranked against 
samples containing regular TNF during analysis. 
Expected Outcomes:  
The overall outcome of this aim will be comprehensive knowledge of structure 
and makeup of TNF and its respective polymorphisms upon Ebola infection. This 
knowledge will be used to identity individuals with key polymorphisms that lower TNF 
production. 
Potential Pitfalls and Possible Alternatives:  
It will be difficult to ensure samples from unexposed individuals in surrounding 
areas of Beni are actually unexposed. If we are unable to obtain enough samples to 
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conduct a thorough analysis, we will use samples from individuals in the US who have 
not traveled to the DRC, so as to ensure complete unexposure.  
Specific Aim 2: To determine the role of TNF in Ebola disease progression. 
Introduction:  
The objective of this aim is to determine how production of TNF in an Ebola-
infected individual affects disease progression. The working hypothesis of this aim is 
that low levels of TNF production will be protected against death from Ebola. 
Conversely, our hypothesis also includes that high levels of TNF will be associated with 
greater mortality from Ebola disease. Our approach to testing this working hypothesis 
will be to use ELISA assays to examine levels of TNF at different intervals upon 
infection.  
Justification and Feasibility:  
There is previous literature indicating that infection with Ebolavirus promotes 
production of TNF. Hensley et al conducted a study in 2002 where they collected sera 
and plasma from nonhuman primates and assayed the samples to determine levels 
production of several different cytokines (Hensley et al, 2002). Samples were taken pre-
exposure (before they were purposefully infected), at the early stage of disease (2-3 
days post infection), late stage of disease (5-6 days post infection), and the terminal 
stage of disease (6-7 days post infection). There were no detectable cytokines observed 
in the early disease stages. By day 5, there was increased IFN and TNF-alpha in 75% 
of the samples. Infection was lethal to all nonhuman primates infected. This indicates 
that there is an initial release of TNF, followed by a drop in production and then a 
gradual increase.  
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Fig. 1. Analysis of cytokine accumulation in EBOV-infected nonhuman primates. EBOV represents 
infectious Ebolavirus, EBOV-g represents inactivated ebolavirus. (Hensley et al, 2002) 
Research Design:  
This aim will involve several extractions of blood samples from recently infected 
individuals. First, individuals who were recently infected must be identified in the Beni 
General Hospital. Determining how recent the infection was will be the responsibility of 
the Hospital staff to inform us when diagnosis occurred. The earlier the diagnosis, the 
more accurate our results will be. Once infected individuals are identified, blood 
samples will be taken at predetermined intervals throughout their disease progression. 
These intervals are at diagnosis, at the early stage of disease (2-3 days post infection), 
late stage of disease (5-6 days post infection), and the terminal stage of disease (6-7 
days post infection). Each sample will be stored properly until the ELISA assay to 
ensure that they were not corrupted or damaged, affecting our results. Once samples 
are determined to be intact, they are to be assayed by using commercially available 
ELISA kits according to manufacturer’s directions to measure TNF levels. The different 
levels will be observed over time, allowing us to determine any trends in TNF production 
upon Ebolavirus infection.  
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Expected Outcomes:  
The overall outcome of this aim will be an understanding of the role of TNF in 
Ebola disease progression. This knowledge will be used to determine which individuals 
have a higher risk of mortality upon infection.  
Potential Pitfalls and Possible Alternatives:  
Our working hypothesis is that the higher levels of TNF produced will increase 
the chance of mortality in an individual. This requires that we perform ELISA assays at 
predetermined checkpoints before and after infection with Ebolavirus. Missing a 
checkpoint or incorrectly determining that checkpoint will result in inconsistent data. It 
can be difficult to determine exact checkpoints since it will be difficult to determine when 
exactly individuals were infected. To ameliorate this potential mishap, we will ensure 
that there are multiple reminders put in place to remind the staff of when to take 
measurements, as well as alerting staff at the Beni Treatment Center to record exactly 
when infection was diagnosed.  
Use of Human Subjects:  
This study involves the analysis of human blood samples to be collected at the 
Beni Ebola Treatment Center and surrounding areas. Although usually painless, there is 
a small risk of a cut to the skin from the needle used for extraction, or lightheadedness 
from extracting too much blood. The Beni General Hospital (where the Ebola Treatment 
Center is found) has been collecting blood samples since its inception, and therefore 
the staff is well trained in how to obtain blood samples with minimal to no injury to the 
individual.  
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